The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.
AbbVie today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback